Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Trevena is a biotechnology business based in the US. Trevena shares (TRVN) are listed on the NASDAQ and all prices are listed in US Dollars. Trevena employs 35 staff and has a market cap (total outstanding shares value) of 0.00.
Finder Award
SoFi Invest
Finder Award
eToro
tastytrade
| Latest market close | $1.16 |
|---|---|
| 52-week range | $0.58 - $12.22 |
| 50-day moving average | $0.91 |
| 200-day moving average | $2.56 |
| Wall St. target price | $20.00 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-5.29 |
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an adviser or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $1.16 from 2023-05-30
| 1 week (2023-05-25) | 7.41% |
|---|---|
| 1 month (2023-05-01) | 85.01% |
| 3 months (2023-03-01) | 12.62% |
| 6 months (2022-12-01) | -66.38% |
| 1 year (2022-05-31) | 272.03% |
|---|---|
| 2 years (2021-06-01) | -35.56% |
| 3 years (2020-06-01) | 1.33 |
| 5 years (2018-06-01) | 1.8 |
| Operating margin TTM | 11585.18% |
|---|---|
| Gross profit TTM | $-3,436,000 |
| Return on assets TTM | -60.91% |
| Return on equity TTM | -151.47% |
| Profit margin | 0% |
| Book value | $1.13 |
| Market capitalisation | $12.6 million |
TTM: trailing 12 months
We're not expecting Trevena to pay a dividend over the next 12 months.
Trevena's shares were split on a 1:25 basis on 10 November 2022. So if you had owned 25 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Trevena shares – just the quantity. However, indirectly, the new 2400% higher share price could have impacted the market appetite for Trevena shares which in turn could have impacted Trevena's share price.
Over the last 12 months, Trevena's shares have ranged in value from as little as $0.58 up to $12.22. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Trevena's is 2.0461. This would suggest that Trevena's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Trevena, Inc. , a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain. Trevena, Inc. was incorporated in 2007 and is based in Chesterbrook, Pennsylvania. .
Access remote advice, planning and portfolio management from this established financial services company.
Steps to owning and managing ET, with 24-hour and historical pricing before you buy.
Steps to owning and managing UEC, with 24-hour and historical pricing before you buy.
Steps to owning and managing GROY, with 24-hour and historical pricing before you buy.
The best trading apps come with low fees and are easy to use.
Here’s what happens to your securities if your brokerage fails, and how your assets are protected by SIPC and FDIC.
Learn about buying physical gold, plus stocks and ETFs, to learn how you can add gold exposure to your portfolio.
Several ETFs have exposure to Silicon Valley Bank, but it appears minimal.
Treasury Bills are fixed-income assets with maturities of less than one year. Here’s what to know before investing.
The 16th largest US bank has collapsed, but its impact on your portfolio could be limited depending on what you own.